Covalent coupling of Spike?s receptor binding domain to a multimeric carrier produces a high immune response against SARS-CoV-2

M. FLORENCIA PIGNATARO; PAULA BERGUER; MATIAS BLAUSTEIN; LUIS BREDESTON; PATRICIO CRAIG; CECILIA D'ALESSIO; FERNANDA ELIAS; PAULA FARRÉ; NATALIA FERNANDEZ; GENTILI, HERNÁN; YAMILA GANDOLA; JAVIER GASULLA; GUSTAVO GUDESBLAT; HERRERA, MARÍA GEORGINA; IBAÑEZ LORENA ITATI; TOMAS IDROVO; NADRA, ALEJANDRO DANIEL; DIEGO NOSEDA; CARLOS PAVÁN; MARIA FLORENCIA PAVAN; ROMÁN ERNESTO; RUBERTO LUCAS; NATALIA RUBINSTEIN; MARIA VICTORIA SANCHEZ; SANTOS, JAVIER; WETZLER DIANA; ALICIA ZELADA

Scientific Reports

Springer Nature

Año: 2022

The receptor binding domain (RBD) of the Spike protein from SARS-CoV-2 is a promising candidate to develop effective COVID-19 vaccines since it can induce potent neutralizing antibodies. We have previously reported the highly efficient production of RBD in Pichia pastoris, which is structurally similar to the same protein produced in mammalian HEK-293T cells. In this work we designed an RBD multimer with the purpose of increasing its immunogenicity. We produced multimeric particles by a transpeptidation reaction between RBD expressed in P. pastoris and Lumazine Synthase from Brucella abortus (BLS), which is a highly immunogenic and very stable decameric 170 kDa protein. Such particles were used to vaccinate mice with two doses 30 days apart. When the particles ratio of RBD to BLS units was high (6?7 RBD molecules per BLS decamer in average), the humoral immune response was significantly higher than that elicited by RBD alone or by RBD-BLS particles with a lower RBD to BLS ratio (1?2 RBD molecules per BLS decamer). Remarkably, multimeric particles with a high number of RBD copies elicited a high titer of neutralizing IgGs. These results indicate that multimeric particles composed of RBD covalent coupled to BLS possess an advantageous architecture for antigen presentation to the immune system, and therefore enhancing RBD immunogenicity. Thus, multimeric RBD-BLS particles are promising candidates for a protein-based vaccine.